Who are Aripiprazole+ ADT's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aripiprazole-adt.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Aripiprazole+ ADT — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aripiprazole+ ADT (Aripiprazole+ ADT) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic combined with androgen deprivation therapy. Area: Psychiatry / Oncology.

phase 3 Atypical antipsychotic combined with androgen deprivation therapy Dopamine D2/D3 receptors (aripiprazole component); androgen receptor (ADT component) Psychiatry / Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Aripiprazole+ ADT (Aripiprazole+ ADT) — Otsuka Pharmaceutical Development & Commercialization, Inc.. Aripiprazole is a dopamine D2/D3 receptor partial agonist combined with an androgen deprivation therapy (ADT) agent to treat psychiatric symptoms in patients undergoing hormone therapy.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aripiprazole+ ADT TARGET	Aripiprazole+ ADT	Otsuka Pharmaceutical Development & Commercialization, Inc.	phase 3	Atypical antipsychotic combined with androgen deprivation therapy	Dopamine D2/D3 receptors (aripiprazole component); androgen receptor (ADT component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic combined with androgen deprivation therapy class)

Otsuka Pharmaceutical Development & Commercialization, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aripiprazole+ ADT — Competitive Intelligence Brief. https://druglandscape.com/ci/aripiprazole-adt. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing